Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

enGene Therapeutics Inc. Common Stock

ENGN

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Last trade $1.71
Day change -$0.18 (-9.52%)
Day range $1.68 – $1.97
Volume 1,343,641
Market cap $127M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$126.66M
Price / earnings
—
Price / book
0.55×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.82×

Profitability

Earnings per share
-$1.95
Return on assets
-45.21%
Return on equity
-56.61%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.11×
Current ratio
10.21×
Quick ratio
10.21×
Cash ratio
1.51×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$104M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ENGN, quarterly periods
Line itemQ3 FY2026 Jul 31, 2026Q2 FY2026 Apr 30, 2026Q1 FY2026 Jan 31, 2026Q4 FY2025 Oct 31, 2025Q3 FY2025 Jul 31, 2025Q2 FY2025 Apr 30, 2025Q1 FY2025 Jan 31, 2025Q4 FY2024 Oct 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$13.92M$9.77M$8.93M$7.76M$7.37M$6.92M$6.64M$6.18M
Research and development$20.09M$22.2M$22.26M$31.72M$22.58M$20.21M$19.97M$11.27M
Total operating expenses$34.01M$31.97M$31.19M$39.48M$29.95M$27.12M$26.61M$17.46M
Operating income-$34.01M-$31.97M-$31.19M-$39.48M-$29.95M-$27.12M-$26.61M-$17.46M
Interest expense-$843K-$745K-$732K-$750K-$758K-$734K-$752K-$756K
Income before taxes-$32.5M-$30.23M-$29.75M-$38.38M-$28.75M-$25.58M-$24.6M-$15.28M
Income taxes$0$0$0-$497K$239K$240K$18K$19K
Net income-$32.5M-$30.23M-$29.75M-$37.88M-$28.99M-$25.82M-$24.62M-$15.3M
Net income attributable to common shareholders-$32.5M-$30.23M-$29.75M-$37.88M-$28.99M-$25.82M-$24.62M-$15.3M
EBITDA-$33.84M-$31.79M-$31M-$39.31M-$29.82M-$27.02M-$26.51M-$17.37M
Basic earnings per share-$0.47-$0.43-$0.44-$0.74-$0.57-$0.51-$0.48-$0.35
Diluted earnings per share-$0.47-$0.43-$0.44-$0.74-$0.57-$0.51-$0.48-$0.35

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications

Junshi Biosciences announced that China's NMPA has accepted new drug applications for JS001sc, a subcutaneous formulation of toripalimab (anti-PD-1 monoclonal antibody), across 12 tumor indications. The Phase 3 clinical trial demonstrated non-inferior drug exposure and comparable efficacy and safety compared to intravenous administration, marking the first domestic anti-PD-1 subcutaneous formulation to reach the marketing application stage.

Benzinga

Why AppLovin Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Shares of AppLovin Corporation (NASDAQ: APP) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results. AppLovin reported quarterly earnings of 49 cents per share which beat the analyst consensus estimate of 36 cents. The company reported quarterly sales of $953.26 million, beating the analyst consensus estimate of $928.17 million. AppLovin shares jumped 22.3% to $57.30 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers China Natural Resources, Inc. (NASDAQ: CHNR) gained 409% to $5.60 in pre-market trading after gaining around 10% on Wednesday. Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA) shares jumped 70.2% to $1.89 in pre-market trading after surging around 19% on Wednesday. SoundHound AI, Inc. (NASDAQ: SOUN) gained 69.8% to $3.83 in pre-market trading. According to data from Benzinga Pro, BlackRock reported a 5.6% passive stake in SoundHound AI after the market close. Traders also appear to be circling a filing from Nvidia in which the ...

Benzinga

Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures trading higher by around 70 points on Thursday. Shares of Cisco Systems, Inc. (NASDAQ: CSCO) fell in today’s pre-market trading following second-quarter results. Cisco reported better-than-expected second-quarter financial results but issued weak full-year 2024 guidance. The company also announced a restructuring plan to cut approximately 5% of its global workforce. Cisco Systems shares fell 5.2% to $47.68 in pre-market trading. Here are some big stocks recording losses in today’s pre-market trading session. Nu Skin Enterprises, Inc. (NYSE: NUS) shares dipped 24% to $13.25 ...

Benzinga

Dow Edges Higher; QuidelOrtho Shares Plummet

U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Wednesday. The Dow traded up 0.11% to 38,313.27 while the NASDAQ rose 0.70% to 15,765.18. The S&P 500 also rose, gaining, 0.49% to 4,977.43. Check This Out: Snap, American Express And 2 Other Stocks Insiders Are Selling   Leading and Lagging Sectors   Industrials shares rose by 1.1% on Wednesday. In trading on Wednesday, consumer staples shares fell by 0.6%.   Top Headline   Crude oil inventories in the U.S. surged by 12.018 million barrels in the week ending Feb. 9, compared to market estimates of a 2.56 million rise.   Equities Trading UP   enGene Holdings Inc. (NASDAQ: ENGN) shares shot up 83% to $13.95. The company’s CEO Jason Hanson is resigning due to personal family and health reasons, though he will continue to support the company as a strategic advisor after a successor is appointed. Concurrently, enGene announced a private placement of 20 million common shares at $10.00 per share, representing a 31% premium over the previous day’s closing price. Shares of Lyft, Inc. (NASDAQ:

Benzinga

Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list its financial arm in October 2025. Sony Group reported third-quarter FY23 sales growth of 22% year-on-year to $25.34 billion (¥3.75 trillion), beating the consensus of $24.62 billion. Adjusted EPS of $1.99 beat the consensus of $1.65. Sony revised its FY23 sales outlook to $86.62 billion (¥12.4 trillion), down from a prior forecast of ¥12.3 trillion versus the consensus of $87.32 billion. Sony Group shares fell 6.3% to $89.86 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Datasea Inc. (NASDAQ: DTSS) shares jumped 1,173% to $18.59. On Tuesday, Datasea posted a narrower second-quarter loss. Earlyworks Co., Ltd. (NASDAQ: ELWS) surged 416% to $2.35 on two passive stakes. enGene Holdings Inc. (NASDAQ: ENGN) jumped 95.5% to $14.90. The company’s CEO Jason Hanson is resigning due to personal family and health reasons, though he will continue to support the company as a strategic advisor after a successor is appointed. Concurrently, enGene announced a private placement of 20 million common shares at $10.00 per share, representing a 31% premium over the previous day’s closing price. Cineverse Corp. (NASDAQ: CNVS) surged 92.9% to $2.9899. Cineverse announced forthcoming launch of AI-powered movie search platform cineSearch. Cheche Group Inc. (NASDAQ: CCG) gained 74.3% to $5.49. MGO Global, Inc. (NASDAQ: MGOL) rose 66% to $0.6647. Cogent Biosciences, Inc. (NASDAQ: COGT) surged 62.7% to $8.89. Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) gained 35% to $1.29 after the company announced it received the first ever U.S. Patent approval for an orbiting blood oxygenation delivery system, a core technology of the INSPIRA ART500 device. Lyft, Inc. (NASDAQ: LYFT) shares gained 34.3% to $16.29 after the company reported fourth-quarter sales of $1.22 billion and gross bookings of $3.7 ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Aug 3, 2015$0.1263Aug 7, 2015recurring
Jul 1, 2015$0.1251Jul 8, 2015recurring
Jun 1, 2015$0.1251Jun 5, 2015unknown
May 1, 2015$0.1219May 7, 2015recurring
Apr 1, 2015$0.1294Apr 8, 2015recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.